Prolapse GenitaleLASVNCT03534830
A Novel Assay for Predicting Surgical Outcomes in Pelvic Organ Prolapse
An observational study of Prolapse Genital, run by University of South Florida at 1 site in United States.
Trial summary
The research objective of this proposal is to investigate the clinical utility and validity of eLASV as a personalized marker for women's individual risk of recurrence for pelvic organ prolapse following advanced surgical procedures. Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Prolapse Genital
- What is being tested?
- MRI
- How many people
- 51 participants
- Where
- 1 siteUnited States
- Study dates
- 2 Feb 2018to 1 Jan 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Study population: We will recruit 50 women total with symptomatic stage III pelvic organ prolapse who elect to proceed with surgical intervention within the Division of Urogynecology at University of South Florida (USF) Department of Obstetrics and Gynecology.
Who may be able to join
- Greater than or equal to 18 years old
- English speaking
- Willing to sign an informed consent
- Stage III pelvic organ prolapse
- Undergoing uterosacral ligament suspension for pelvic organ prolapse Exclusion Criteria
- Women who do not meet the inclusion criteria.
- Inability to undergo a pelvic MRI
- Having a different apical suspension procedure for pelvic organ prolapse
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Estimated Levator Ani Subtended Volume (eLASV): A Novel Assay for Predicting Surgical Outcomes in Pelvic Organ Prolapse
The research objective of this proposal is to investigate the clinical utility and validity of eLASV as a personalized marker for women's individual risk of recurrence for pelvic organ prolapse following advanced surgical procedures. Estimated levator ani subtended volume (eLASV) is a reproducible magnetic resonance image of the female pelvis that objectively quantifies the integrity of the pelvic floor levator ani muscles. A woman's levator ani muscle anatomical shape is unique to her as a result of her own individual lifetime risk for development of pelvic floor dysfunction. The novelty of eLASV as a measurement of muscle integrity, separates it methodology from the solitary of diagnosing partial trauma or defects as previously published within the literature. eLASV measurements have the potential to identify women at increased risk for surgical failure and may be used as a prognostic tool to aid in future counseling and stratification of patients into surgical options for treatment of pelvic organ prolapse.
Read the detailed description
Pelvic floor disorders affect millions of women within the United States daily, with nearly 25% of all women currently have some form of pelvic floor dysfunction [1]. An estimated 200,000 women undergo surgery annually for pelvic organ prolapse [4-6], and recent projections estimate that the number will increase to approximately 250,000 by year 2050 [7]. Up to 30% of these women, will undergo a second surgical procedure for recurrence of prolapse following their first surgery [2]. Astoundingly, resulting in 60,000 - 75,000 women a year undergoing a second advanced gynecological surgical procedure for pelvic organ prolapse consequently increasing the patients' perioperative risk and the overall cost of women's healthcare nationwide.
Levator ani muscle plays an important role in pelvic support. Weakening or direct trauma to the muscle is currently the best-defined pathogenesis for development of pelvic organ prolapse and for the recurrence of prolapse after surgical repair [7-13]. Levator ani avulsion has been demonstrated to be a clinical predictor of cystocele recurrence following anterior colporrhaphy with native tissue and with mesh augmentation [11,12]. However, further studies are warranted to investigate of levator ani muscle integrity as a predictor for surgical outcomes after more advance surgical procedures.
The investigators demonstrated an objective measure of levator ani muscle integrity (eLASV) calculated from standard 2D dynamic pelvic MRI measurements (H-line and M-line) obtained directly from radiology reports along with one 2D linear measurement that is easily obtained from radiographic images [13-15]. The novelty of eLASV as a measurement of the entire muscle integrity, separates it methodology from the solitary of diagnosing partial trauma or defects as previously published within the literature. eLASV is a novel objective measurement of levator ani muscle integrity and measures all three portions of the muscle (puborectalis, pubococcygeus, and iliococcygeus) as a whole complex. Transvaginal and transperineal ultrasonography along with CT scans or xRays of the pelvic floor are unable to image at the high level resolution imperative for complete reconstruction of the entire levator ani muscle.
Each woman's levator ani muscle anatomical shape is unique to her as a result of her own individual lifetime risk for developement of pelvic floor dysfunction. Consider the levator ani muscle as a kitchen bowl varying in different shapes and sizes for each individual woman. Now consider filling these varying shapes and sizes of the kitchen bowls with water, eLASV is the objective three dimensional measurement of the volume of water contained within each different muscle complex.
When the volume of eLASV is elevated, it represents a measurable change in the anatomical shape of the muscle as a result of loss of the muscle integrity for support of the pelvic floor. As Decreased support of the levator ani muscle within the pelvic floor will result in an increased strain on the supportive ligament structures within the female pelvis [16,17]. Increased strain on the supportive structures including the uterosacral ligament, sacrospinous ligament, paravaginal support, etc., could result in an increased risk of recurrence for prolapse following advance pelvic reconstructive surgery.
eLASV may have the potential to identify women at increased risk for surgical failure and could be used as a prognostic tool to aid in future counseling of patients on surgical options for treatment of pelvic organ prolapse. Identification of women at an increased risk for surgical failure following advanced surgical procedures would be invaluable in a surgical subspecialty that has a reoperation rate as high as 30% after a primary surgery [2].
Personalized medicine and patient selection thus far has played a very small role in the discussion regarding the use of mesh versus native tissue repair in female pelvic reconstructive surgery. Patient stratification into certain reconstructive procedures will likely change once clinicians become better at diagnosing levator ani trauma and identify patients at high risk of prolapse recurrence after reconstructive surgery [8]. Abdominally placed mesh, either via robotically, laparoscopically, or open, for a sacral colpopexy is considered the gold standard for apical suspension in patients with pelvic organ prolapse [18]. However, there is an increased concern for the use of synthetic mesh in reconstructive pelvic surgery [19].
This study represents a step in the direction of identifying patients at increased risk for surgical failure and the potential of stratifying future patients into specific surgical procedures based on their own individual likelihood of success vs failure after an advanced pelvic reconstructive procedure improving patient outcomes.
Approach: The specific aims of this project will be fulfilled through a combined qualitative and quantitative approach. The investigators plan to test the feasibility of executing a prospective cohort trial investigating the clinical utility of eLASV as a preoperative biomarker and prognostic tool to predict surgical outcomes in pelvic organ prolapse by assessing the study design/process, resources available, management and time barriers, along with the scientific merit of the study. The investigators will also plan to test the validity of eLASV calculation and pilot test eLASV as a biomarker at 38.5 to predict surgical outcomes for laparoscopic uterosacral ligament suspension. The investigators will then use the information gathered from our pilot study to refine or modify the research methodology to develop a larger, NIH grant supported prospective cohort control trial.
- Conditions
- Prolapse Genital
- Being tested
- MRI
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MRIDiagnostic test
pre-operative MRI to be performed on all patients and then based on the imaging studies, the patient will be divided into the two comparative cohorts
| Study group | Role | What they receive |
|---|---|---|
| eLASV > 38.5 | exposed group of patients with an eLASV at or above 38.5 on a pre-operative MRI. Receives: Diagnostic Test: MRI | |
| eLASV < 38.5 | non-exposed group of patients with an eLASV less than 38.5 of pre-operative MRIs Receives: Diagnostic Test: MRI |
What is being measured
The primary outcome is the main question the study is designed to answer.
Surgical failure after apical prolapse repair
Surgical failure will be a single composite outcome that will be defined by any of the following information: presence of anatomic bulge beyond the hymen (within any compartment: anterior, posterior, or apical), sensation of a symptomatic vaginal bulge, or the need for repeat treatment for prolapse via pessary or surgery
Measured: one year
Secondary outcomes (3)
Repeatability of measurement
Repeatability of MRI measurements to calculate eLASV
Measured: one year
Reliability of measurement-inter observer
Inter observer reliability of measurements of 2d images to calculate eLASV
Measured: one year
Reliability of measurement intra observer
Intra-observer reliability of measurements of 2d images to calculate eLASV
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 May 2018
- Study start2 Feb 2018
- Primary completion31 Dec 2020
- Study completion1 Jan 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Prolapse GenitalStudies of the same condition, open and under way.
- More trials run by University of South FloridaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 51 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of South Florida
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03534830
- Sponsor's protocol ID
- 00031263
- Acronym
- eLASV
- Status last verified
- Oct 2021
- First submitted
- 15 Mar 2018
- Last updated
- 7 Oct 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Wyman AM, Salemi JL, Lai-Yuen S, Greene KA, Bassaly R, Kedar R, Hoyte L. Estimated Levator Ani Subtended Volume: A Predictive Biomarker for Surgical Outcomes Following Native Tissue Apical Repair. Female Pelvic Med Reconstr Surg. 2022 Jun 1;28(6):385-390. doi: 10.1097/SPV.0000000000001142. Epub 2022 Mar 4.
PubMed 35234178
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Estimated Levator Ani Subtended Volume (eLASV): A Novel Assay for Predicting Surgical Outcomes in Pelvic Organ Prolapse
- ClinicalTrials.gov ID
- NCT03534830
- Acronym / sponsor ID
- eLASV / 00031263
- Conditions
- Prolapse Genital
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 51 participants (actual)
- Lead sponsor
- University of South FloridaUniversity, hospital or other
- Study start
- 2 Feb 2018 (actual)
- Primary completion
- 31 Dec 2020 (actual)
- Study completion
- 1 Jan 2021 (actual)
- First posted
- 23 May 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The research objective of this proposal is to investigate the clinical utility and validity of eLASV as a personalized marker for women's individual risk of recurrence for pelvic organ prolapse following advanced surgical procedures. Estimated levator ani subtended volume (eLASV) is a reproducible magnetic resonance image of the female pelvis that objectively quantifies the integrity of the pelvic floor levator ani muscles. A woman's levator ani muscle anatomical shape is unique to her as a result of her own individual lifetime risk for development of pelvic floor dysfunction. The novelty of eLASV as a measurement of muscle integrity, separates it methodology from the solitary of diagnosing partial trauma or defects as previously published within the literature. eLASV measurements have the potential to identify women at increased risk for surgical failure and may be used as a prognostic tool to aid in future counseling and stratification of patients into surgical options for treatment of pelvic organ prolapse.
Detailed description
Pelvic floor disorders affect millions of women within the United States daily, with nearly 25% of all women currently have some form of pelvic floor dysfunction [1]. An estimated 200,000 women undergo surgery annually for pelvic organ prolapse [4-6], and recent projections estimate that the number will increase to approximately 250,000 by year 2050 [7]. Up to 30% of these women, will undergo a second surgical procedure for recurrence of prolapse following their first surgery [2]. Astoundingly, resulting in 60,000 - 75,000 women a year undergoing a second advanced gynecological surgical procedure for pelvic organ prolapse consequently increasing the patients' perioperative risk and the overall cost of women's healthcare nationwide.
Levator ani muscle plays an important role in pelvic support. Weakening or direct trauma to the muscle is currently the best-defined pathogenesis for development of pelvic organ prolapse and for the recurrence of prolapse after surgical repair [7-13]. Levator ani avulsion has been demonstrated to be a clinical predictor of cystocele recurrence following anterior colporrhaphy with native tissue and with mesh augmentation [11,12]. However, further studies are warranted to investigate of levator ani muscle integrity as a predictor for surgical outcomes after more advance surgical procedures.
The investigators demonstrated an objective measure of levator ani muscle integrity (eLASV) calculated from standard 2D dynamic pelvic MRI measurements (H-line and M-line) obtained directly from radiology reports along with one 2D linear measurement that is easily obtained from radiographic images [13-15]. The novelty of eLASV as a measurement of the entire muscle integrity, separates it methodology from the solitary of diagnosing partial trauma or defects as previously published within the literature. eLASV is a novel objective measurement of levator ani muscle integrity and measures all three portions of the muscle (puborectalis, pubococcygeus, and iliococcygeus) as a whole complex. Transvaginal and transperineal ultrasonography along with CT scans or xRays of the pelvic floor are unable to image at the high level resolution imperative for complete reconstruction of the entire levator ani muscle.
Each woman's levator ani muscle anatomical shape is unique to her as a result of her own individual lifetime risk for developement of pelvic floor dysfunction. Consider the levator ani muscle as a kitchen bowl varying in different shapes and sizes for each individual woman. Now consider filling these varying shapes and sizes of the kitchen bowls with water, eLASV is the objective three dimensional measurement of the volume of water contained within each different muscle complex.
When the volume of eLASV is elevated, it represents a measurable change in the anatomical shape of the muscle as a result of loss of the muscle integrity for support of the pelvic floor. As Decreased support of the levator ani muscle within the pelvic floor will result in an increased strain on the supportive ligament structures within the female pelvis [16,17]. Increased strain on the supportive structures including the uterosacral ligament, sacrospinous ligament, paravaginal support, etc., could result in an increased risk of recurrence for prolapse following advance pelvic reconstructive surgery.
eLASV may have the potential to identify women at increased risk for surgical failure and could be used as a prognostic tool to aid in future counseling of patients on surgical options for treatment of pelvic organ prolapse. Identification of women at an increased risk for surgical failure following advanced surgical procedures would be invaluable in a surgical subspecialty that has a reoperation rate as high as 30% after a primary surgery [2].
Personalized medicine and patient selection thus far has played a very small role in the discussion regarding the use of mesh versus native tissue repair in female pelvic reconstructive surgery. Patient stratification into certain reconstructive procedures will likely change once clinicians become better at diagnosing levator ani trauma and identify patients at high risk of prolapse recurrence after reconstructive surgery [8]. Abdominally placed mesh, either via robotically, laparoscopically, or open, for a sacral colpopexy is considered the gold standard for apical suspension in patients with pelvic organ prolapse [18]. However, there is an increased concern for the use of synthetic mesh in reconstructive pelvic surgery [19].
This study represents a step in the direction of identifying patients at increased risk for surgical failure and the potential of stratifying future patients into specific surgical procedures based on their own individual likelihood of success vs failure after an advanced pelvic reconstructive procedure improving patient outcomes.
Approach: The specific aims of this project will be fulfilled through a combined qualitative and quantitative approach. The investigators plan to test the feasibility of executing a prospective cohort trial investigating the clinical utility of eLASV as a preoperative biomarker and prognostic tool to predict surgical outcomes in pelvic organ prolapse by assessing the study design/process, resources available, management and time barriers, along with the scientific merit of the study. The investigators will also plan to test the validity of eLASV calculation and pilot test eLASV as a biomarker at 38.5 to predict surgical outcomes for laparoscopic uterosacral ligament suspension. The investigators will then use the information gathered from our pilot study to refine or modify the research methodology to develop a larger, NIH grant supported prospective cohort control trial.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| eLASV > 38.5 | – | Diagnostic Test: MRIexposed group of patients with an eLASV at or above 38.5 on a pre-operative MRI. |
| eLASV < 38.5 | – | Diagnostic Test: MRInon-exposed group of patients with an eLASV less than 38.5 of pre-operative MRIs |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- We will recruit 50 women total with symptomatic stage III pelvic organ prolapse who elect to proceed with surgical intervention within the Division of Urogynecology at University of South Florida (USF) Department of Obstetrics and Gynecology.
Key inclusion criteria (8 listed)
- Greater than or equal to 18 years old
- English speaking
- Willing to sign an informed consent
- Stage III pelvic organ prolapse
- Undergoing uterosacral ligament suspension for pelvic organ prolapse Exclusion Criteria
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MRIpre-operative MRI to be performed on all patients and then based on the imaging studies, the patient will be divided into the two comparative cohorts | Diagnostic test | eLASV < 38.5, eLASV > 38.5 |
Primary outcome
Surgical failure after apical prolapse repair
Time frame: one year
Surgical failure will be a single composite outcome that will be defined by any of the following information: presence of anatomic bulge beyond the hymen (within any compartment: anterior, posterior, or apical), sensation of a symptomatic vaginal bulge, or the need for repeat treatment for prolapse via pessary or surgery
3 secondary outcomes
Repeatability of measurement
Time frame: one year
Reliability of measurement-inter observer
Time frame: one year
Reliability of measurement intra observer
Time frame: one year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2021.
- Derived from this study: PubMed 35234178Wyman AM, Salemi JL, Lai-Yuen S, Greene KA, Bassaly R, Kedar R, Hoyte L. Estimated Levator Ani Subtended Volume: A Predictive Biomarker for Surgical Outcomes Following Native Tissue Apical Repair. Female Pelvic Med Reconstr Surg. 2022 Jun 1;28(6):385-390. doi: 10.1097/SPV.0000000000001142. Epub 2022 Mar 4.
- Individual participant dataSharing planned: Undecided
Related trials for Prolapse Genital
Active, not recruitingObservational study
i-Stitch for Bilateral Sacrospinous Ligament Fixation (SSLF)
Pelvic Organ Prolapse, Genital Prolapse
Recruiting
Pelvic Floor Muscle Training During Pregnancy
Urinary Incontinence, Anal Incontinence
Not yet recruiting
Perineal Protection Device for Reducing Perineal Trauma During Vaginal Delivery in First-time Mothers: a Multicenter Randomized Controlled Trial
Pelvic Floor Dysfunction, Perineal Laceration
Active, not recruiting
Patient-Centered Outcomes in the Surgical Treatment of Uterovaginal Prolapse
Uterine Prolapse
Recruiting
Functional Links Between the Temporomandibular Joint and the Pelvis in Gynecology
Prolapse; Female, Endometriosis-related Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Prolapse Genital, run by University of South Florida at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Surgical failure after apical prolapse repair (time frame: one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03534830, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2021.